Fig. 7: Aged mice treated with maraviroc have fewer TCNs in BM and increased bone mass.

a, b Frequencies (a) and numbers (b) of TCNs in BM of 22-mon-old male C57 mice treated with vehicle or maraviroc (10 mg/kg) once/d s.c. for 1 month. Mean±SD (n = 9 and 10 biologically independent male mice for vehicle and maraviroc-treated groups, respectively). c–e μCT 3D reconstruction of L1 vertebrae (c) and values for trabecular bone volume (BV/TV) (d) and thickness (Tb.Th) (e). Bar = 1 mm. Mean ± SD (n = 9 and 10 biologically independent male mice, respectively). f–h Horizontal sections of μCT 3D reconstruction of cortical bones of L1 vertebrae (f) and values for cortical bone thickness (Cort.Th) (g) and bone mineral density (BMD) (h). Bar = 1 mm. Mean ± SD (n = 9 and 10 biologically independent male mice, respectively). (i, j) Bone formation parameters including mineral apposition rate (MAR) and bone formation rate (BFR) in L1 vertebrae. Mean ± SD (n = 9 and 10 biologically independent male mice, respectively). k H&E-stained sections of L2 vertebrae and l OB surface values. Bar = 50 μm. Mean ± SD (n = 9 and 10 biologically independent male mice, respectively). m Serum osteocalcin by ELISA. Mean ± SD (n = 5 and 4 biologically independent male mice, respectively). n TRAP-stained paraffin sections as in (k), OC numbers (o), and surfaces (p). Bar = 50 μm. Mean ± SD (n = 9 and 10 biologically independent male mice, respectively). q Serum TRACP-5b by ELISA. Mean ± SD (n = 5 and 4 biologically independent male mice, respectively). Analyses: Student’s two-sided unpaired t test. Source data are provided as a Source data file.